Arrowhead Pharmaceuticals, Inc. (ARWR) analyst actions
Rating and price-target actions on ARWR in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the ARWR overview →
8 measured ARWR analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia | Press release | +1.89% | +0.39% | |
| Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies | Press release | +2.94% | +2.25% | |
| Arrowhead Pharmaceuticals Initiates Phase 3 YOSEMITE Study of Investigational Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia | Press release | +1.01% | +3.85% | |
| Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity | Press release | +2.90% | +1.36% | |
| Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity | Press release | +0.64% | +1.28% | |
| Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease | Press release | -1.43% | -1.90% | |
| Arrowhead Pharmaceuticals Initiates Expanded Access Program for Plozasiran and Announces Upcoming Presentation of Clinical Data | Press release | +1.64% | +2.12% | |
| Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy | Press release | +1.40% | -0.39% |
Keep exploring
More ARWR: earnings → · SEC filings → · ARWR overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Karyopharm Therapeutics Inc. (KPTI) | 392 | -0.45% | 45% |
| Rubius Therapeutics, Inc. (RUBY) | 392 | -0.32% | 45% |
| Axsome Therapeutics, Inc. (AXSM) | 391 | +0.05% | 52% |
| RA PHARMACEUTICALS (RARX) | 391 | -0.04% | 45% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.